10288-36-5

Usage

Uses

Used in Chemical Industry:
2,3-dihydro-1,4-benzodioxin-5-ol is used as a versatile compound for various applications in the chemical industry due to its unique molecular structure and stability. Its rigid construct and heterocyclic nature make it suitable for a range of chemical processes and formulations.
While the specific applications of 2,3-dihydro-1,4-benzodioxin-5-ol are not extensively documented, its properties suggest potential uses in the following areas:
1. Pharmaceutical Industry:
2,3-dihydro-1,4-benzodioxin-5-ol could be used as an intermediate in the synthesis of pharmaceutical compounds, given its stability and chemical reactivity.
2. Agrochemical Industry:
In the development of agrochemicals, 2,3-dihydro-1,4-benzodioxin-5-ol might serve as a building block for creating new pesticides or herbicides, leveraging its chemical properties to target specific pests or weeds.
3. Material Science:
The rigid structure of 2,3-dihydro-1,4-benzodioxin-5-ol could be utilized in the creation of new materials with specific mechanical or thermal properties, such as polymers or composites.
4. Flavor and Fragrance Industry:
Given its aromatic nature, 2,3-dihydro-1,4-benzodioxin-5-ol might be used in the development of new fragrances or flavorings, contributing to unique scents or tastes.
5. Research and Development:
In academic and industrial research settings, 2,3-dihydro-1,4-benzodioxin-5-ol could be employed as a model compound to study chemical reactions, mechanisms, or to develop new synthetic methodologies.

InChI:InChI=1/C8H8O3/c9-6-2-1-3-7-8(6)11-5-4-10-7/h1-3,9H,4-5H2

Upstream product

• 106-93-4 ethylene dibromide 
• 87-66-1 2-hydroxyresorcinol 
• 1710-55-0 5-methoxy-2,3-dihydrobenzo[b][1,4]dioxane 
• 154582-36-2 5-Cyanomethoxy-1,4-benzodioxane 

Downstream Products

• 412339-10-7 3-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-propionic acid 
• 154582-36-2 5-Cyanomethoxy-1,4-benzodioxane 
• 42965-39-9 2,3-dihydro-1,4-benzodioxine-5,8-quinone 
• 1710-62-9 5-(2-bromoethoxy)-2,3-dihydrobenzo[b][1,4]dioxine 

Relevant academic research and scientific papers

Studies toward the discovery of the next generation of antidepressants. Part 2: Incorporating a 5-HT1A antagonist component into a class of serotonin reuptake inhibitors

The design and synthesis of a novel series of indole derivatives (9) having dual 5-HT transporter reuptake and 5-HT1A antagonist activity are described.

Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists

By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands' agonistic properties are substantially driven by the presence of an endocyclic H-bond donor.

Synthesis and inhibitory activity of new ethylenedioxyquinones as analogs of coenzyme

A new series of analogs of coenzyme Q, 2,3 ethylenedioxy 5 hydroxy 6 alkyl 1,4 benzoquinones, was synthesized on the basis of the minor differences in the electronic and rotational nature between the 2,3 ethylenedioxy group and 2,3 dimethoxy groups. These differences could affect the redox potential of the 1,4 benzoquinone and, in turn, affect inhibitory activity. The 6 alkyl groups were farnesyl, phytyl, nonyl, decyl, pentadecyl, heptadecyl, and 5' (cyclohexyl)pentyl. The succinoxidase and DPNH oxidase systems of intact mitochondria from beef heart were used in tests for inhibition. The nonyl, decyl, pentadecyl, and farnesyl analogs showed inhibitions of less than 40%; and the phytyl, heptadecyl, and 5' (cyclohexyl)pentyl analogs showed inhibitions of about 50% in succinoxidase. All the analogs were less inhibitory in DPNH oxidase. 2,3 Dimethoxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone showed 91% inhibition at a concentration of 97 nmol of inhibitor/mg of mitochondrial protein, while 2,3 ethylenedioxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone exhibited only 37% inhibition at the higher concentration of 140 nmol of inhibitor/mg of mitochondrial protein in the succinoxidase system. Similarly, this 2,3 dimethoxyquinone was a more potent inhibitor in DPNH oxidase. 2,3 Dimethoxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone showed 91% inhibition at a concentration of 97 nmol of inhibitor/mg of mitochondrial protein, while 2,3 ethylenedioxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone exhibited only 37% inhibition at the higher concentration of 140 nmol of inhibitor/mg of mitochondrial protein in the succinoxidase system. Similarly, this 2,3 dimethoxyquinone was a more potent inhibitor in DPNH oxidase than the corresponding 2,3 ethylenedioxyquinone. Apparently, 2,3 dimethoxy groups are more favorable than the 2,3 ethylenedioxy group on the 5 hydroxy 6 alkyl 1,4 benzoquinone nucleus for inhibition of these two CoQ oxidases.

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines

N-Aryloxylethylindolealkylamines (5) having dual 5-HT transporter and 5-HT1A affinity are described. These compounds represent truncated analogues of our previously reported piperidinyl derivatives (3). Compounds in this investigation were found to have more similar affinities and functional activities for the 5-HT1A receptor and 5-HT transporter. Though 5-HT1A antagonism is not consistently observed throughout series 5, several molecular features were found to be essential to obtain high and balanced activities. The proper placement of a heteroatom in the aryl ring and the length of the linkage used to tether the indole moiety had significant influence on 5-HT1A and 5-HT transporter affinities. Introduction of a halogen into the aryl ring usually lowered intrinsic activity and in some cases led to full 5-HT1A antagonists. Compounds 33 and 34 were observed to be full 5-HT1A antagonists with Ki values of approximately 30 nM for the 5-HT1A receptor and Ki values of 5 and 0.5 nM for the 5-HT transporter, respectively. Unfortunately, similar to our previous series (3), compounds in this report also had high affinity for the α1 receptor.

Azaindole derivatives for the treatment of depression

Compounds useful in the treatment of diseases affected by disorders of the serotonin-affected neurological systems, such as depression and anxiety, are provided having the following formula: wherein: R1and R2form a carbocyclic ring of 5 to 7 carbon atoms, wherein said ring may be saturated or unsaturated and may contain one or more heteroatoms; and X is independently hydrogen, cyano, carbamoyl, halogen or alkoxy; or pharmaceutically acceptable salts thereof.

Heterocyclic compounds

The invention relates to compound of general formula (I): STR1 wherein: Z represents O or CH 2n is from 0 to 4R, X and Y are as defined in the description, andA represents STR2 wherein R 1, R 2, R 6, R 7 and T'' are as defined in the description,and medicinal products containing the same are useful in treating or in preventing melatoninergic disorders.

The use of the cyanomethyl unit as a protecting group for phenols, amines and carbamates

The use of the cyanomethyl unit as a protecting group for phenols, primary and secondary amines, and carbamates is described. Optimized conditions for formation and hydrolysis of cyanomethyl in the presence of the other hydrogenolysis-sensitive groups such as O- and N-benzyl groups are presented.

Synthese de dioxinocoumarines angulaires

The synthesis of angular dioxinocoumarins 1 and 2 connected with angelicins are described.These syntheses are respectively realized in eight and ten steps from 6-amino-1,4-benzodioxane and 3-methoxycatechol.